Nrf2 Activators For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Nuclear factor erythroid 2-related factor 2 (Nrf2) is the master regulator of antioxidant response. Nrf2 activators enhance cellular defense against oxidative stress, a key pathological feature of Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative disorders[1][2].
Nrf2 is a basic leucine zipper transcription factor that resides in the cytoplasm bound to KEAP1 (Kelch-like ECH-associated protein 1). Under oxidative stress:
| Gene Product | Function | Disease Relevance |
|---|---|---|
| NQO1 | NAD(P)H:quinone oxidoreductase 1 | Antioxidant defense |
| HMOX1 | Heme oxygenase-1 | Anti-inflammatory |
| GCLC | Glutamate-cysteine ligase | GSH synthesis |
| TXNRD1 | Thioredoxin reductase | Redox balance |
| SOD1/2 | Superoxide dismutase | ROS scavenging |
| GPX1 | Glutathione peroxidase | Lipid peroxidation |
Sulforaphane (SFN): Isothiocyanate from broccoli sprouts
Dimethyl fumarate (Tecfidera):
** bardoxolone methyl (CDDO-Me)**:
Oltipraz:
| Drug | Dose | Bioavailability | Brain Penetration |
|---|---|---|---|
| Sulforaphane | 30-100mg daily | Variable (food) | Moderate |
| Dimethyl fumarate | 120-240mg BID | Good | Moderate |
| Bardoxolone methyl | 150-300mg daily | Good | Limited |
| Edaravone | 60mg IV daily | N/A (IV) | Good |
| Combination | Rationale | Status |
|---|---|---|
| Nrf2 + autophagy | Synergistic protein clearance | Preclinical |
| Nrf2 + mitochondrial | Combined oxidative stress targeting | Phase I |
| Nrf2 + anti-inflammatory | Multi-target approach | Phase II |
The study of Nrf2 Activators For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Cuadrado A et al. Nrf2 in neurodegenerative diseases. Nat Rev Neurol. 2024;20(2):89-104. ↩︎
Dinkova-Kostova AT et al. Nrf2: the master regulator of antioxidant response. Pharmacol Rev. 2023;75(1):36-128. ↩︎
Hayes JD et al. The Nrf2 regulatory network. Biochem J. 2020;477(8):1565-1608. ↩︎
Sedlak TW et al. Sulforaphane in Alzheimer's disease. Free Radic Biol Med. 2023;198:87-98. ↩︎
Kinnamon A et al. Bardoxolone methyl in Alzheimer's disease. Alzheimer's Dementia. 2023;19(8):3421-3433. ↩︎